Business: R&D and marketing of biopharmaceuticals and diagnostics
Biotech Revenue: Rs 21 crore
CEO: IA Modi (Chairman)
Start-up Year: 1995
Address: Sarkhej-Dholka Road, Bhat, Ahmedabad-382 210
Cadila Pharmaceuticals (CPL) in
creased its biotechnology turnover to Rs 21 crore in 2006-07 against the previous year's sales revenue of Rs 17 crore. Cadila Pharmaceuticals has about 20 products including conventional and recombinant vacancies, anti-cancer biotherapeutics, diagnostics using recombinant antigens and natural thrombolites in its basket. Some of its brand includes Immuvac, VISIAL, Halonix and STPase. It has also developed technologies like diagnostics for HIV, thrombolites for Myocardial infarction and a probiotic.
Biotechnology is a thrust area of research at Cadila Pharmaceuticals. Currently a team of 30 scientists headed by Dr P K Ghosh is working on different projects. About half a dozen products are in the pipeline for immuno-prophylaxis, diagnosis of hepatitis C, therapeutics for cancer, viral hepatitis, diabetes mellitus and anemia.
In the area of biotechnology research, Cadila Pharmaceuticals believes in collaborative research and development. Hence it has entered into tie-ups with half a dozen national and international research laboratories like IMTECH, Chandigarh, NII and CBT, New Delhi, ICGEB, New Delhi & Trieste, Italy. It has set up a research facility at IISc, Bangalore. About 70 people are actively into manufacturing of biotech products. n